As consensus analyst forecasts for Zydus Lifesciences’ revenue growth and future P/E remained virtually unchanged, the fair value estimate also held steady at ₹1007.
What's in the News
- Zydus Therapeutics reported positive topline results for Saroglitazar in the EPICS-III Phase 2(b)/3 trial for Primary Biliary Cholangitis, meeting both primary and secondary endpoints; a US regulatory submission is planned for early 2026, and the drug has Orphan Drug and Fast Track Designations from the USFDA.
- Zydus received final USFDA approvals for Diltiazem Hydrochloride Tablets and Prucalopride Tablets, as well as tentative approval for Ibrutinib Tablets, collectively targeting lucrative US markets.
- The company received final USFDA approval for Celecoxib Capsules for various pain and inflammation indications.
- Zydus secured its first Notice of Compliance from Health Canada for Varenicline tablets, marking entry into the Canadian market.
- Multiple manufacturing sites, including those in Ahmedabad, Baddi, and Dabhasa, cleared recent USFDA and Health Canada inspections with no or minor observations, supporting regulatory compliance and future product launches.
Valuation Changes
Summary of Valuation Changes for Zydus Lifesciences
- The Consensus Analyst Price Target remained effectively unchanged, at ₹1007.
- The Future P/E for Zydus Lifesciences remained effectively unchanged, moving only marginally from 34.32x to 34.29x.
- The Consensus Revenue Growth forecasts for Zydus Lifesciences remained effectively unchanged, at 6.1% per annum.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.